Owen Mumford Brand Guidelines: Oxford 1952, Autopen, Autoject & Aidaptus

An Oxford workshop, a laryngoscope and a set of bellows.

Owen Mumford was founded in Oxford in 1952. The company says its founders, Ivan Owen and John Mumford, met while serving apprenticeships in Oxfordshire and shared an ambition to run their own business; the timeline on its website also lists Thomas Owen alongside them as a founder. Its first product, the company says, was a version of the Macintosh laryngoscope, made with the instrument’s inventor, Professor Sir Robert Macintosh, to an improved design that was easier for doctors to use.

Oxford’s hospitals and university shaped the early range. In 1953, the company says, it began making the Oxford Inflating Bellows, a light, portable device for artificial respiration designed with the university’s Nuffield Department of Anaesthetics, and in 1954 a humidifier used during operations, first called the Radcliffe Humidifier after the Oxford infirmary where a doctor had asked for it. In 1959 an order from New York’s civil defence authorities for 2,000 sets of bellows, with some of the glass parts remade in plastic, led the company to move to Woodstock, Oxfordshire, and to set up a plastics division.

Plastics became the core skill. By 1965, the company says, it was making its own injection moulds and turning out around 50 million plastic components and some 5,000 medical instruments a year. In the 1970s it worked with doctors at the Radcliffe Infirmary’s diabetes research laboratory, and in 1978 it introduced the Autolet, a device for taking a small blood sample from a fingertip, created with Robert Turner and Rury Holman of the Radcliffe and described by the company as the world’s first automatic lancing device. Diabetes care would shape the next half-century of the business.

Pens, autoinjectors and needles, for patients and for drug companies.

The diabetes devices followed one another through the 1980s. The company dates its Accupen, a pen that delivered a preset number of insulin units, to 1980, and the Autopen insulin pen to 1982: a slim, portable device that held a cartridge of insulin and let the user dial a dose, with a release button mounted on the side. In 1986 came Autoject, which Owen Mumford describes as the world’s first plastic autoinjector. In 2002, the company says, Autopen gained versions for children and teenagers, among them the brightly coloured Autopen Junior.

Needles and lancets became the volume business. The Unistik single-use blood-sampling device arrived in 1994 and was later redesigned with fewer parts as Unistik 2 and Unistik 3. The Unifine Pentips Plus pen needle, with a second chamber for taking off and storing the used needle, followed in 2011, after focus groups showed that people with limited dexterity found changing needles awkward, the company says; Unifine SafeControl came in 2019. The company lists a Queen’s Award for export in 1999 and Queen’s Awards for innovation in 2008, for Unistik 3, and in 2017, for Unifine Pentips Plus.

Alongside its own brands, Owen Mumford designs and makes devices for drug companies through its pharmaceutical services division. It launched UniSafe, now called EcoSafe, a springless device for prefilled syringes, in 2017, and in 2021 Aidaptus, a two-step, single-use autoinjector that takes both 1 mL and 2.25 mL prefilled syringes. The company says Aidaptus won a Red Dot Award for product design in 2023. Its website now groups the wider range into drug delivery, blood collection, eye care, neuropathy and pelvic health.

How drug-delivery makers present themselves.

Drug-delivery device makers sell mostly to other companies. Their customers are pharmaceutical and biotech firms that fill a pen, an autoinjector or a prefilled syringe with their own medicine and put their own name on the box, so the device maker’s brand often lives one step back from the patient. That shapes how these companies present themselves: less as consumer brands, more as engineering partners that can be trusted with a drug company’s product.

The pictures follow from that. The typical image is a clean render of a pen or autoinjector on a white or pale ground, often shown from several angles or in a technical cutaway that reveals the spring, the plunger and the syringe inside. Product families are usually named as platforms, with one prefix running across a range, and shown in neutral greys and whites so that a customer can imagine its own colours on the device.

Production is the other recurring theme. Websites and brochures show cleanroom assembly lines, injection-moulding machines, operators in gowns and hairnets, and gloved hands holding glass syringes, cartridges and vials. These images carry the message that the work is precise and controlled, and they sit beside pages on quality systems, regulatory support and human-factors testing with patients.

Much of the industry’s public face is seen at trade shows. Makers book stands at events such as CPHI, the pharmaceutical ingredients and packaging fair, Pharmapack in Paris, and the conferences of the Parenteral Drug Association, where they show new platforms to drug companies. The visual language there is the same: white stands, large product renders, cutaway models and short films of devices being assembled and used.

A privately held Oxfordshire maker joins embecta.

Owen Mumford stayed privately held for more than seven decades and kept its roots in Oxfordshire. The company says it opened a factory in the Cotswolds in 1992, in its fortieth year, moved its moulding to Chipping Norton in 1993, built a larger Cotswold facility in 2005 for autoinjectors made with drug companies, opened a site in Malaysia in 2015, where production of Unistik 3 and Autopen began, and in 2023 opened a production site in Witney, Oxfordshire, which it calls a centre for automation and assembly. Its website now lists the Chipping Norton site as its head office. It says it runs in-house injection moulding and automated assembly lines in clean rooms, and it became a certified B Corp in 2021.

On 19 March 2026 the American company embecta, the former diabetes business of BD, announced a definitive agreement to buy Owen Mumford Holdings, Drug Delivery Business News reported, and the same publication reported that the deal was completed on 15 May 2026. embecta, based in Parsippany, New Jersey, said the purchase would speed its move towards becoming a broad-based medical supplies company that provides drug delivery platforms to pharmaceutical companies, with Aidaptus named as a central asset. Owen Mumford’s website now describes it as “part of embecta” and says its heritage and values remain at the heart of the business.

For a design guide, Owen Mumford shows how a maker can keep a family of plain product names, from Autolet to Autoject to Aidaptus, recognisable across seventy years. Compare Ypsomed, a Swiss maker of pens and autoinjectors for drug companies, and BD, the group where embecta began. For this guide we use a deep navy, a warm cream and an amber with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep Owen Mumford’s identity on hand — save it to a board in the Made Good inspiration library.